Replies to post #5010 on Galena Biopharma fka GALE

[BooDog]

We'll see. Milestone achieved or soon to be?

Research and Development Expenses — Research and development costs are expensed as incurred. Included in research and development costs are wages, benefits and other operating costs, facilities, supplies, external services and overhead related to our research and development departments, and clinical trial expenses.


Clinical trial expenses include direct costs associated with contract research organizations ("CROs"), as well as well as patient-related costs at sites at which our trials are being conducted.


Direct costs associated with our CROs are generally payable on a time and materials basis, or when certain enrollment and monitoring milestones are achieved. Expense related to a milestone is recognized in the period in which the milestone is achieved or in which we determine that it is more likely than not that it will be achieved.


The invoicing from clinical trial sites can lag several months. We accrue these site costs based on our estimate of upfront set-up costs upon the screening of the first patient at each site, and the patient related costs based on our knowledge of patient enrollment status at each site.

http://www.sec.gov/Archives/edgar/data/1390478/000139047814000024/gale-20140331x10q.htm

Just guessing that it may have something to do with one of the trials getting ready to move forward further.

"forward further" hmmmmmm Going into ASCO as well. Maybe there'll be something good to go along with that. :-)

Holding the 20dma so far.

[JonathanTel]

http://www.sec.gov/Archives/edgar/data/1390478/999999999714009589/filename1.pdf

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
May 12, 2014

ORDER GRANTING CONFIDENTIAL TREATMENT
UNDER THE SECURITIES EXCHANGE ACT OF 1934

Galena Biopharma, Inc.

File No. 001-33958 - CF#30863
_____________________

Galena Biopharma, Inc. submitted an application under Rule 24b-2 requesting
confidential treatment for information it excluded from the Exhibits to a Form 10-K filed
on March 17, 2014.

Based on representations by Galena Biopharma, Inc. that this information
qualifies as confidential commercial or financial information under the Freedom of
Information Act, 5 U.S.C. 552(b)(4), the Division of Corporation Finance has determined
not to publicly disclose it. Accordingly, excluded information from the following
exhibit(s) will not be released to the public for the time period(s) specified:

Exhibit 2.1 through March 17, 2019
Exhibit 10.36 through January 13, 2024
Exhibit 10.37 through December 20, 2016

For the Commission, by the Division of Corporation Finance, pursuant to
delegated authority:



Kevin M. O’Neill
Deputy Secretary